Trinity Biotech Statistics
Total Valuation
Trinity Biotech has a market cap or net worth of $11.05 million. The enterprise value is $143.89 million.
Important Dates
The next estimated earnings date is Tuesday, June 30, 2026, before market open.
| Earnings Date | Jun 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Trinity Biotech has 18.72 million shares outstanding. The number of shares has increased by 19.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 18.72M |
| Shares Change (YoY) | +19.73% |
| Shares Change (QoQ) | +2.71% |
| Owned by Insiders (%) | 3.02% |
| Owned by Institutions (%) | 4.10% |
| Float | 14.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.25 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25
| Current Ratio | 0.25 |
| Quick Ratio | 0.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.45 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.72% |
| Return on Invested Capital (ROIC) | -15.65% |
| Return on Capital Employed (ROCE) | 26.48% |
| Weighted Average Cost of Capital (WACC) | 12.01% |
| Revenue Per Employee | $109,190 |
| Profits Per Employee | -$93,207 |
| Employee Count | 401 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.41 |
Taxes
In the past 12 months, Trinity Biotech has paid $199,000 in taxes.
| Income Tax | 199,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.18% in the last 52 weeks. The beta is 0.87, so Trinity Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -19.18% |
| 50-Day Moving Average | 0.65 |
| 200-Day Moving Average | 0.90 |
| Relative Strength Index (RSI) | 39.57 |
| Average Volume (20 Days) | 65,440 |
Short Selling Information
The latest short interest is 402,865, so 3.82% of the outstanding shares have been sold short.
| Short Interest | 402,865 |
| Short Previous Month | 291,283 |
| Short % of Shares Out | 3.82% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.19 |
Income Statement
In the last 12 months, Trinity Biotech had revenue of $43.79 million and -$37.38 million in losses. Loss per share was -$2.00.
| Revenue | 43.79M |
| Gross Profit | 16.89M |
| Operating Income | -9.55M |
| Pretax Income | -37.18M |
| Net Income | -37.38M |
| EBITDA | -6.86M |
| EBIT | -9.55M |
| Loss Per Share | -$2.00 |
Full Income StatementBalance Sheet
The company has $5.14 million in cash and $137.98 million in debt, with a net cash position of -$132.85 million or -$7.10 per share.
| Cash & Cash Equivalents | 5.14M |
| Total Debt | 137.98M |
| Net Cash | -132.85M |
| Net Cash Per Share | -$7.10 |
| Equity (Book Value) | -71.98M |
| Book Value Per Share | -3.76 |
| Working Capital | -105.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.93 million and capital expenditures -$88,000, giving a free cash flow of -$6.02 million.
| Operating Cash Flow | -5.93M |
| Capital Expenditures | -88,000 |
| Depreciation & Amortization | 2.68M |
| Net Borrowing | 11.81M |
| Free Cash Flow | -6.02M |
| FCF Per Share | -$0.32 |
Full Cash Flow StatementMargins
Gross margin is 38.57%, with operating and profit margins of -21.80% and -85.36%.
| Gross Margin | 38.57% |
| Operating Margin | -21.80% |
| Pretax Margin | -84.91% |
| Profit Margin | -85.36% |
| EBITDA Margin | -15.67% |
| EBIT Margin | -21.80% |
| FCF Margin | n/a |
